84611-23-4

Basic information

• Product Name: Erdosteine
• Synonyms: 2-[2-OXO-2-(2-OXO-TETRAHYDROTHIOPHEN-3-YLAMINO)ETHYLTHIO]ACETIC ACID;[[2-oxo-2-[(tetrahydro-2-oxo-3-thienyl)amino]ethyl]thio]acetic acid;ERDOSTEINE;((2-oxo-2-((tetrahydro-2-oxo-3-thienyl)amino)ethyl)thio)-aceticaci;acide((2-oxo-3-tetrahydrothienylcarbamoyl)-methylthio)acetique;dl-s-(2-(n-3-(2-oxotetrahydrotheinyl)acetamido))thioglycolicacid;pv144;ERDOSTEINE BP98
• CAS NO: 84611-23-4
• Molecular Formula: C₈H₁₁NO₄S₂
• Molecular Weight: 249.31
• EINECS: 1312995-182-4
• Product Categories: Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds;SECRESOLV
• Mol File: 84611-23-4.mol
• Article Data: 3

Chemical Properties

• Melting Point: 156-160°C
• Boiling Point: 590.4 °C at 760 mmHg
• Flash Point: 310.8 °C
• Appearance: white or almost white crystalline powder
• Density: 1.48 g/cm³
• Vapor Pressure: 1.82E-15mmHg at 25°C
• Refractive Index: 1.615
• Storage Temp.: Refrigerator
• Solubility: Acetonitrile (Slightly), DMSO (Slightly), Methanol (Slightly)
• PKA: 3.71(at 25℃)
• Merck: 14,3647
• CAS DataBase Reference: Erdosteine(CAS DataBase Reference)
• NIST Chemistry Reference: Erdosteine(84611-23-4)
• EPA Substance Registry System: Erdosteine(84611-23-4)

Safety Data

• RTECS: AJ1476200
• Hazardous Substances Data: 84611-23-4(Hazardous Substances Data)

Usage

Description

Different sources of media describe the Description of 84611-23-4 differently. You can refer to the following data:
1. Erdosteine is a new expectorant introduced in France for the treatment of chronic bronchitis. Erdosteine possesses mucomodulator, mucolytic, mucokinetic and free radical scavenging properties. Its therapeutic efficacy has been demonstrated in patients affected by congestion and viscous mucus in higher and lower respiratory tracts as in acute and chronic bronchitis, sinusitis, otitis, tracheopharyngitis and coryza. Erdosteine acts through its active metabolites containing free sulfhydryl groups which are able to depolymerize the mucopolysaccharides of the excreatum by breaking the disulfide linkages (thereby lowing its viscosity). The prodrug approach provides unique characteristics to erdosteine by offering stable therapeutic efficacy and prevention of the gastric mucus from lythic phenomena. The agent was also reported to have local antiinflammatory and antielastase properties and enhances penetration of antibiotics into bronchial mucus.
2. Erdosteine is a mucolytic agent and an antioxidant. It inhibits LPS-induced IκB kinase (IKK) activity, NF-κB-mediated transcription, and production of IL-6 and IL-1β in RAW 264.7 cells. Erdosteine (7.5 mg/kg) prevents depletion of renal catalase and glutathione peroxidase (GPX) and increases in renal malondialdehyde (MDA) and nitric oxide (NO) levels in a rat model of nephrotoxicity induced by cisplatin . It reduces spinal cord lipid peroxidation and destruction of spinal motor neurons in a rabbit model of spinal cord ischemia and reperfusion injury induced by thoracoabdominal aortic clamping. Erdosteine (150 mg/kg) reduces lung weight, MDA and protein carbonyl levels, and macrophage and neutrophil accumulation in a mouse model of acute lung injury induced by oleic acid (Item Nos. 90260 | 24659). Formulations containing erdosteine have been used in the treatment of chronic obstructive pulmonary disease (COPD).

Chemical Properties

Off-White Solid

Originator

Refarmed (Switzerland)

Uses

Different sources of media describe the Uses of 84611-23-4 differently. You can refer to the following data:
1. A mucolytic, developed for the treatment of chronic obstructive bronchitis.
2. Erdosteine is a mucolytic. Erdosteine was developed for the treatment of chronic obstructive bronchitis.

Brand name

Edirel; Vectrine

InChI:InChI=1/C8H11NO4S2/c10-6(3-14-4-7(11)12)9-5-1-2-15-8(5)13/h5H,1-4H2,(H,9,10)(H,11,12)

Upstream product

• 3261-87-8 1,4-oxathiane-2,6-dione 
• 10593-85-8 DL-homocysteine thiolactone 
• 68-11-1 mercaptoacetic acid 
• 84611-22-3 N-chloroacetylhomocysteine thiolactone 

Relevant articles and documents

Preparation method of thioglycolic anhydride

The invention discloses a preparation method of thioglycolic anhydride. The method comprises the following steps of: vaporization of trifluoroacetic anhydride: vaporizing trifluoroacetic anhydride ina vaporizing device for later use; synthesis of thioglycolic anhydride: preheating the interior of a suspended gas-solid reaction device to 45-65 DEG C, introducing the vaporized trifluoroacetic anhydride into the suspended-state gas-solid reaction device, intermittently adding thionyl diacetic acid from the top of the suspended-state gas-solid reaction device, reacting for 2 hours, stopping introducing the vaporized trifluoroacetic anhydride from a gas inlet, stopping heating, and leading out an obtained solid product from a discharging port; and purification of thioglycolic anhydride: washing the solid product with refrigerated anhydrous petroleum ether and anhydrous ether respectively to obtain pure thioglycolic anhydride. The thioglycolic anhydride synthesized by the method is high inpurity and high in yield; and the yield of erdosteine prepared by reacting the thioglycolic anhydride serving as a raw material with homocysteine thiolactone hydrochloride is high.

[(2-Oxo-3-tetrahydrothienylcarbamoyl)-alkylthio] acetic acids, their salts and esters, a process for preparation thereof and the pharmaceutical compositions containing same

The present invention relates to [(2-oxo-3-tetrahydrothienylcarbamoyl)-alkylthio]-acetic acids, their salts and esters of formula: STR1 in which n is 0 or 1, one of the substituents R1 and R2 is a hydrogen atom or a methyl group and the other represents a group -S-CH2 -COOR3, where R3 is a hydrogen atom or an alkali metal or a lower alkyl group or a group: STR2 It also relates to a process for preparing said acids, salts and esters, and to the drugs containing same.